Sequential therapies with sorafenib and sunitinib in advanced or metastatic renal cell carcinoma.

e15061 Background: There is increasing evidence to suggest that patients with metastatic renal cell carcinoma (mRCC) benefit from sequential therapies with the tyrosine kinase inhibitors (TKIs) sorafenib and sunitinib. Our goal was to compare overall progression-free survival (PFS) and overall survival (OS) between mRCC patients who were treated with sorafenib followed by sunitinib and patients who received the reciprocal sequence. Methods: 89 patients were treated in nine German centres between 2002 and 2009. The TKI sequence started as first-, second- or third-line therapy after prior chemo- or immunotherapy. When progression was diagnosed, treatment was switched to the second TKI until further progression. Results: Overall progression-free survival (PFS) of patients receiving sunitinib followed by sorafenib shows no statistically significant difference to patients receiving sorafenib followed by sunitinib (15.4 vs. 12.1 months). The secondary use of sorafenib resulted in a median PFS of 3.8 months if t...